Rapamycin: one drug, many effects

Cell Metab. 2014 Mar 4;19(3):373-9. doi: 10.1016/j.cmet.2014.01.001. Epub 2014 Feb 6.

Abstract

The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth and metabolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as cancer, diabetes, obesity, neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and the potential utility of combination therapy with rapamycin.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Aging / drug effects
  • Drug Therapy, Combination
  • Humans
  • Longevity / drug effects
  • Lung Diseases / drug therapy
  • Lung Diseases / metabolism
  • Lung Diseases / pathology
  • Metabolic Diseases / drug therapy
  • Metabolic Diseases / metabolism
  • Metabolic Diseases / pathology
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Nervous System Diseases / drug therapy
  • Nervous System Diseases / metabolism
  • Nervous System Diseases / pathology
  • Signal Transduction / drug effects*
  • Sirolimus / pharmacology*
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • TOR Serine-Threonine Kinases
  • Sirolimus